NAD+ — nicotinamide adenine dinucleotide — is not a peptide. It is a dinucleotide: two nucleotide halves, one carrying nicotinamide and one carrying adenine, joined tail to tail through a pyrophosphate bridge. It contains no amino acid residues and no peptide bonds, so none of the reasoning a lab applies to peptide identity — sequence confirmation, residue-level purity, deamidation of an asparagine — transfers to it. It sits in a peptide catalog because the researchers who work on cellular energetics order it alongside peptides, not because it shares a chemical class with them.

The molecule does two distinct jobs that are frequently discussed as though they were one. In the first it acts as a catalyst: it accepts a hydride, becomes NADH, hands the hydride on and is regenerated unchanged, so one molecule can turn over indefinitely. In the second it acts as a consumable substrate: a family of enzymes cleaves the bond between nicotinamide and its ribose, destroying the molecule to produce a signaling product. The redox job explains why NAD+ is abundant. The consumption job explains why its concentration moves at all, and why the field treats NAD+ as a regulated quantity rather than a fixed background constant [1].

Identity

These are the values Echo Peptides publishes for this compound, and the ones a receiving lab should reconcile against an incoming certificate of analysis.

Two notes on reading that block. First, the plus sign in "NAD+" is not the net charge of the molecule. It records the quaternized nitrogen of the nicotinamide ring, which is what distinguishes the oxidized species from NADH; the pyrophosphate bridge carries negative charges of its own, and at neutral pH the assembled molecule is anionic overall. The formula above is the free acid, and it is the free acid mass that the reconstitution table on the product page uses — 500 mg taken up in 1 mL of diluent is 754 mM only because 500 mg is divided by 663.4 g/mol. A hydrate, or a sodium salt of the same compound, weighs more per mole and would shift every molarity in that table downward. If a certificate of analysis reports a salt or hydrate form, the molarity should be recalculated against the mass on the certificate rather than assumed from the free-acid figure.

Second, a dinucleotide with two phosphate groups is not a molecule that crosses a lipid bilayer on its own. That fact organizes most of what follows, because it means the concentration of NAD+ inside any compartment is set by synthesis, degradation and dedicated transport in that compartment — not by how much NAD+ is in the surrounding medium.

The redox role

The NAD+/NADH pair is the hydride carrier that links substrate oxidation to energy transduction. In mitochondria it is what connects oxidation of carbon substrates by the tricarboxylic acid cycle to ATP generation by the electron transport chain and oxidative phosphorylation [2]. Because the molecule is regenerated at each pass, what matters biochemically in this role is not the total amount present but the ratio of oxidized to reduced forms, and that ratio differs between compartments of the same cell. A dehydrogenase assay reports on the ratio available to it; it does not report on the cell.

This distinction is why measurement method is a design decision rather than a detail. Traditional methods for measuring NADH are either destructive or unable to distinguish it from NADPH, which is a chemically different cofactor with its own pool and its own physiological function. Genetically encoded sensors address those limitations, allowing real-time tracking and quantitative measurement of subcellular NADH levels in living cells, each type with its own advantages and disadvantages [3]. Which sensor was used, and how it was calibrated, is part of the result rather than a detail of it.

The consumption role

Three enzyme families, plus one specialized executioner, spend NAD+ rather than recycling it.

Sirtuins

Sirtuins are NAD+-dependent deacetylases: they remove acetyl groups from lysine residues and, in doing so, cleave NAD+ and release nicotinamide. The mechanism is proposed to proceed through an ADP-ribosyl-peptidyl-imidate intermediate formed from NAD+ and an acetyllysine residue, a proposal for which chemical probes including nicotinamide antagonists and thioacetyl compounds provide key support. Because both the substrate and the product sit in the same reaction, sirtuin activity responds dynamically to intracellular fluctuations of NAD+ and of nicotinamide — nicotinamide is a product inhibitor, not merely a leftover. The same family has since been shown to regulate post-translational modifications beyond acetyl, including succinyl and malonyl [4].

Poly(ADP-ribose) polymerases

PARP1 is a DNA damage sensor, activated rapidly in a manner that scales with the amount and complexity of the damage, and it builds poly(ADP-ribose) chains using NAD+ as the ADP-ribose donor. The cell-wide consequences of that consumption have been imaged directly. Using laser microirradiation to create damage in defined nuclei, combined with phasor-approach fluorescence lifetime imaging and fluorescence biosensors, one group observed a rapid cell-wide increase in the bound NADH fraction triggered by PARP-dependent NAD+ depletion, linked to a metabolic shift toward oxidative phosphorylation over glycolysis. In that system, inhibiting oxidative phosphorylation — but not glycolysis — produced parthanatos through rapid PARP-dependent ATP deprivation, indicating that the shift was a survival response in the damaged cells rather than an incidental byproduct [5].

CD38

CD38 is an NAD glycohydrolase and, in mouse tissue, the principal driver identified for the fall in NAD+ with age. Its expression and activity increase with aging, and it is required for the age-related NAD decline and accompanying mitochondrial dysfunction through a pathway mediated at least in part by regulation of SIRT3 activity. The same work identified CD38 as the main enzyme degrading the NAD precursor nicotinamide mononucleotide in vivo, which means the enzyme that lowers the pool also consumes the molecule most often used to raise it [6].

A later study located much of that activity in a specific cell population. Pro-inflammatory M1-like macrophages — but not naive or M2 macrophages — accumulate in visceral white adipose tissue and liver during aging in mice, express high levels of CD38 and show enhanced CD38-dependent NADase activity. Senescent cells accumulate in the same tissues over the same period, and cytokines of the senescence-associated secretory phenotype induced macrophages to proliferate and to express CD38. The authors describe a causal link among resident tissue macrophages, cellular senescence and tissue NAD decline; they did not show that this is the only route by which the pool falls [7].

SARM1

SARM1 sits at the center of a program that depletes NAD+ in injured axons. Its Toll/interleukin-1 receptor (TIR) domain was shown to have intrinsic NADase activity in purified protein from mammalian cells, bacteria and a cell-free translation system, cleaving NAD+ into ADP-ribose, cyclic ADP-ribose and nicotinamide, with nicotinamide acting as a feedback inhibitor of the enzyme. In traumatic and chemically induced neuronal injury models, the NADase activity of full-length SARM1 was required in axons for NAD+ depletion and subsequent degeneration; the authors' broader conclusion is that the widely used TIR domain is a protein motif that can possess enzymatic activity [8]. It is a direct demonstration that NAD+ loss can be an actively executed program rather than a passive shortfall.

Where the pool comes from, and what actually enters a cell

Because NAD+ itself does not diffuse across membranes, the intracellular pool is built by salvage from smaller precursors. The published cell biology of those precursors is more complicated than the marketing around them suggests, and the findings below are worth stating precisely.

Nicotinamide riboside is imported into cells by members of the equilibrative nucleoside transporter family, and once inside it is predominantly metabolized by purine nucleoside phosphorylase, which cleaves it to nicotinamide. Inhibiting that enzyme prevented the cleavage across several mammalian cell types and potentiated NAD synthesis from nicotinamide riboside; in mice, pairing pharmacological inhibition of the enzyme with nicotinamide riboside strongly reduced cleavage to nicotinamide and sustained higher riboside levels in blood, kidney and liver, and stimulated nicotinamide mononucleotide and NAD+ synthesis, particularly in kidney [9]. The precursor, in other words, is largely dismantled before it is used.

The same literature is candid that the standard precursors move the pool modestly. Work introducing the reduced forms notes directly that nicotinamide mononucleotide and nicotinamide riboside are limited by their mild effect on the cellular NAD+ pool, and reports that reduced nicotinamide mononucleotide is a more potent NAD+ precursor in mammalian cells and in mice, metabolized through a route independent of the nicotinamide riboside kinase and nicotinamide phosphoribosyltransferase pathways [10]. A second group, synthesizing the same reduced compound by its own method, likewise found it a better NAD+ enhancer than nicotinamide mononucleotide in cells and in mice, and reported in addition that it raised NADH levels in cells and in mouse liver; in their metabolomic analysis it inhibited glycolysis and the tricarboxylic acid cycle, and in vitro it induced cell cycle arrest and suppressed cell growth [11]. A reduced precursor is therefore not simply a stronger version of an oxidized one: in that work it moved both members of the redox pair, and central carbon metabolism with them.

The pool is not one pool

The single most consequential finding for anyone designing an NAD+ experiment is that whole-cell measurement can be flat while a compartment collapses. Two groups independently identified SLC25A51 (also called MCART1) as a mammalian mitochondrial NAD+ transporter in 2020, after the existence of such a carrier in mammals had been genuinely controversial. Loss of SLC25A51 decreased mitochondrial — but not whole-cell — NAD+ content, impaired mitochondrial respiration and blocked NAD+ uptake into isolated mitochondria, while overexpression increased mitochondrial NAD+ and restored uptake into yeast mitochondria lacking their endogenous transporters [12]. Cells null for the same gene showed large decreases in tricarboxylic acid cycle flux, mitochondrial respiration, complex I activity and mitochondrial NAD+ and NADH, and the human and yeast transporters functionally complemented one another [2].

Spatial heterogeneity extends to tissue as well. Combining laser-capture microdissection with HPLC to measure NAD+ in small samples, one group found that NAD+ was significantly decreased in the arcuate nucleus, ventromedial hypothalamus and lateral hypothalamus of 22-month-old mice compared with 3-month-old mice, but not in the dorsomedial hypothalamus. Nicotinamide mononucleotide raised NAD+ in all of these nuclei, while extracellular vesicles containing extracellular nicotinamide phosphoribosyltransferase, purified from young mice, raised NAD+ in the arcuate and dorsomedial nuclei [13]. A homogenate of that whole structure would have averaged those differences away.

Handling and solution behavior

The compound ships as a lyophilized powder and the product page specifies refrigerated storage at 2–8 °C and reconstitution in water or bacteriostatic water. Two practical points follow from the chemistry rather than from convention.

Buffer choice is not neutral. A factorial study of cofactor stability followed by UV-visible spectrophotometry found that pH, temperature and buffer identity each measurably affected oxidation of the reduced form over 40 minutes, with no appreciable interaction between the factors, and that phosphate buffer degraded it faster than Pipes — an effect the authors attributed to adduct formation between phosphate and the pyridine ring [14]. Note the scope carefully: what was followed there was oxidation of NADH, the reduced member of the pair, and the pH conclusions belong to that form rather than to the oxidized one supplied here. The transferable point is narrower and still worth having: the buffer a stock is made up in is an experimental variable in its own right, and a working solution prepared in phosphate is not automatically interchangeable with one prepared in something else.

The second point is concentration. A 500 mg vial taken up in 1 mL is 754 mM. Stocks at that strength are made to be diluted heavily, and the ionic contribution of the stock itself is worth accounting for when it is added to a defined assay buffer.

What is not established

The mechanistic literature above is largely cell and rodent work, and its authors are more cautious than secondary summaries of it. A 2024 review by three of the field's principal investigators is explicit that much about the biology of NAD+ and related molecules remains poorly understood, and it catalogs limitations, assumptions and unappreciated factors — including the role of the microbiome in modulating availability — that bear on whether raising NAD+ produces the effects attributed to it, and on where the risks might be [1].

Several specific gaps are worth naming. The causal arrow between falling NAD+ and the phenotypes it accompanies is established in particular models with particular manipulations, not in general. The transporter work identified a mitochondrial NAD+ carrier; it did not identify a plasma-membrane NAD+ transporter, and the assumption that extracellular NAD+ enters cells intact should not be imported from it [2, 12]. The precursor studies show that what is added to a medium and what reaches the NAD+ pool need not be the same molecule: nicotinamide riboside is predominantly cleaved to nicotinamide by purine nucleoside phosphorylase before it can be used, and the reduced form of nicotinamide mononucleotide is metabolized through a route independent of the nicotinamide riboside kinase and nicotinamide phosphoribosyltransferase pathways [9, 10]. And the analytical problem is real: total NAD+ in a lysate is a summary statistic over compartments with different ratios, and it can be unchanged while the quantity that matters to a given enzyme has moved.

For research use only. Not intended for human consumption, veterinary use, or any clinical application.